Geoff Chong

1.0k total citations
25 papers, 414 citations indexed

About

Geoff Chong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Geoff Chong has authored 25 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Geoff Chong's work include Colorectal Cancer Treatments and Studies (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cancer Treatment and Pharmacology (6 papers). Geoff Chong is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cancer Treatment and Pharmacology (6 papers). Geoff Chong collaborates with scholars based in Australia, United Kingdom and United States. Geoff Chong's co-authors include David Cunningham, Francesca Negri, A. Norman, Paul J. Ross, A. Wotherspoon, Eliza A. Hawkes, Andrew Grigg, Danny Rischin, Sheela Rao and Gabriel Kremmidiotis and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Geoff Chong

24 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geoff Chong Australia 9 274 117 111 105 64 25 414
Aimery de Gramont France 9 428 1.6× 120 1.0× 67 0.6× 95 0.9× 67 1.0× 12 548
Jean‐Nicolas Munck France 12 214 0.8× 70 0.6× 137 1.2× 76 0.7× 71 1.1× 21 413
Ashwin R. Sama United States 11 309 1.1× 84 0.7× 74 0.7× 74 0.7× 66 1.0× 26 460
Katia Dotti Italy 12 364 1.3× 149 1.3× 114 1.0× 99 0.9× 91 1.4× 28 514
Seonggyu Byeon South Korea 11 283 1.0× 195 1.7× 128 1.2× 39 0.4× 79 1.2× 30 442
Fa-Chyi Lee United States 9 193 0.7× 156 1.3× 79 0.7× 50 0.5× 124 1.9× 24 385
Ewa Chmielowska Poland 12 251 0.9× 132 1.1× 119 1.1× 47 0.4× 109 1.7× 44 468
Isabelle Genvresse Germany 12 157 0.6× 105 0.9× 104 0.9× 43 0.4× 107 1.7× 27 472
Boyang Chang China 12 224 0.8× 94 0.8× 34 0.3× 90 0.9× 142 2.2× 26 458

Countries citing papers authored by Geoff Chong

Since Specialization
Citations

This map shows the geographic impact of Geoff Chong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoff Chong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoff Chong more than expected).

Fields of papers citing papers by Geoff Chong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoff Chong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoff Chong. The network helps show where Geoff Chong may publish in the future.

Co-authorship network of co-authors of Geoff Chong

This figure shows the co-authorship network connecting the top 25 collaborators of Geoff Chong. A scholar is included among the top collaborators of Geoff Chong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoff Chong. Geoff Chong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sobrero, Alberto, Sara Lonardi, Rocio García‐Carbonero, et al.. (2023). Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.. Journal of Clinical Oncology. 41(4_suppl). 67–67. 5 indexed citations
2.
Eng, Cathy, Arvind Dasari, Sara Lonardi, et al.. (2023). Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.. Journal of Clinical Oncology. 41(16_suppl). 3601–3601.
3.
Dasari, Arvind, Sara Lonardi, Rocio García‐Carbonero, et al.. (2023). Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). 3604–3604. 1 indexed citations
4.
Hawkes, Eliza A., Richard Khor, Sze Ting Lee, et al.. (2022). Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study).. Journal of Clinical Oncology. 40(16_suppl). TPS7587–TPS7587. 1 indexed citations
5.
Roberts, Veena, et al.. (2019). Eculizumab therapy in gemcitabine-induced thrombotic microangiopathy in a renal transplant recipient. Oxford Medical Case Reports. 2019(6). omz048–omz048. 7 indexed citations
6.
Hawkes, Eliza A., et al.. (2018). Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission. British Journal of Cancer. 119(5). 546–550. 9 indexed citations
7.
Lenz, Georg, Eliza A. Hawkes, G. Verhoef, et al.. (2017). CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. Hematological Oncology. 35(S2). 68–69. 6 indexed citations
8.
Hawkes, Eliza A., Andrew Grigg, & Geoff Chong. (2015). Programmed cell death-1 inhibition in lymphoma. The Lancet Oncology. 16(5). e234–e245. 53 indexed citations
9.
Hong, Dae Gy, et al.. (2013). The correlation between expression of synuclein-gamma, glucose transporter-1, and survival outcomes in endometrioid endometrial carcinoma.. PubMed. 34(2). 128–31. 2 indexed citations
10.
Rischin, Danny, David C. Bibby, Geoff Chong, et al.. (2011). Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation. Clinical Cancer Research. 17(15). 5152–5160. 54 indexed citations
11.
Weickhardt, Andrew, Timothy Price, Nick Pavlakis, et al.. (2010). DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.. Journal of Clinical Oncology. 28(15_suppl). 3533–3533. 3 indexed citations
12.
Weickhardt, Andrew, et al.. (2009). Comparison of radiologically inserted arm ports versus surgically placed chest ports for chemotherapy. Asia-Pacific Journal of Clinical Oncology. 5(3). 181–186. 10 indexed citations
13.
Arkenau, Hendrik‐Tobias, Bhawna Sirohi, Geoff Chong, et al.. (2006). Gemcitabine, cisplatin and methylprednisolone (GEM-P) in patients with T-cell lymphoma: Results from The Royal Marsden Hospital. Journal of Clinical Oncology. 24(18_suppl). 17507–17507. 1 indexed citations
14.
Chong, Geoff, Naureen Starling, A. Norman, et al.. (2006). Phase II study of fixed dose rate gemcitabine in patients with pretreated advanced colorectal cancer. Journal of Clinical Oncology. 24(18_suppl). 13558–13558. 2 indexed citations
15.
Chong, Geoff, Anish Bhatnagar, David Cunningham, et al.. (2005). Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Annals of Oncology. 17(3). 437–442. 26 indexed citations
16.
Chong, Geoff, David Cunningham, A. Norman, et al.. (2005). Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. British Journal of Cancer. 93(5). 510–514. 55 indexed citations
17.
Chong, Geoff & David Cunningham. (2005). The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible?. Nature Clinical Practice Oncology. 2(4). 172–173. 4 indexed citations
18.
Negri, Francesca, A. Wotherspoon, David Cunningham, et al.. (2005). Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Annals of Oncology. 16(8). 1305–1310. 123 indexed citations
19.
Chong, Geoff & David Cunningham. (2005). Second-line therapy for advanced colorectal cancer. Current Colorectal Cancer Reports. 1(1). 7–12. 12 indexed citations
20.
Kay, William W., et al.. (1977). Binding of Collagen by Canine Blood Platelets. Thrombosis and Haemostasis. 37(2). 309–320. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aimery de Gramont Breakdown of academic impact, for papers by Jean‐Nicolas Munck Breakdown of academic impact, for papers by Ashwin R. Sama Breakdown of academic impact, for papers by Katia Dotti Breakdown of academic impact, for papers by Seonggyu Byeon Breakdown of academic impact, for papers by Fa-Chyi Lee Breakdown of academic impact, for papers by Ewa Chmielowska Breakdown of academic impact, for papers by Isabelle Genvresse Breakdown of academic impact, for papers by Boyang Chang
Rankless by CCL
2026